JP2023143940A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023143940A5 JP2023143940A5 JP2023119151A JP2023119151A JP2023143940A5 JP 2023143940 A5 JP2023143940 A5 JP 2023143940A5 JP 2023119151 A JP2023119151 A JP 2023119151A JP 2023119151 A JP2023119151 A JP 2023119151A JP 2023143940 A5 JP2023143940 A5 JP 2023143940A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharma
- subject
- combination
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501696P | 2017-05-04 | 2017-05-04 | |
| US62/501,696 | 2017-05-04 | ||
| PCT/US2017/048748 WO2018039642A1 (en) | 2016-08-26 | 2017-08-25 | Compositions and methods thereof |
| USPCT/US2017/048748 | 2017-08-25 | ||
| TW106129169 | 2017-08-28 | ||
| TW106129169A TW201815387A (zh) | 2016-08-26 | 2017-08-28 | 組成物及其方法 |
| US201862634162P | 2018-02-22 | 2018-02-22 | |
| US62/634,162 | 2018-02-22 | ||
| US201862636099P | 2018-02-27 | 2018-02-27 | |
| US201862635554P | 2018-02-27 | 2018-02-27 | |
| US62/635,554 | 2018-02-27 | ||
| US62/636,099 | 2018-02-27 | ||
| US201862636171P | 2018-02-28 | 2018-02-28 | |
| US62/636,171 | 2018-02-28 | ||
| PCT/US2018/030978 WO2018204713A1 (en) | 2017-05-04 | 2018-05-03 | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| JP2019560216A JP7514078B2 (ja) | 2017-05-04 | 2018-05-03 | 新規な組成物、組み合わせ及びその方法を用いた標的薬物救済 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560216A Division JP7514078B2 (ja) | 2017-05-04 | 2018-05-03 | 新規な組成物、組み合わせ及びその方法を用いた標的薬物救済 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023143940A JP2023143940A (ja) | 2023-10-06 |
| JP2023143940A5 true JP2023143940A5 (enExample) | 2024-10-04 |
Family
ID=65431106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560216A Active JP7514078B2 (ja) | 2017-05-04 | 2018-05-03 | 新規な組成物、組み合わせ及びその方法を用いた標的薬物救済 |
| JP2023119151A Pending JP2023143940A (ja) | 2017-05-04 | 2023-07-21 | 新規な組成物、組み合わせ及びその方法を用いた標的薬物救済 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560216A Active JP7514078B2 (ja) | 2017-05-04 | 2018-05-03 | 新規な組成物、組み合わせ及びその方法を用いた標的薬物救済 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3618819A4 (enExample) |
| JP (2) | JP7514078B2 (enExample) |
| KR (2) | KR20200062078A (enExample) |
| CN (1) | CN110831584B (enExample) |
| AU (2) | AU2018261654A1 (enExample) |
| BR (1) | BR112019022902A2 (enExample) |
| CA (2) | CA3138116A1 (enExample) |
| IL (1) | IL270326B2 (enExample) |
| MA (1) | MA49464A (enExample) |
| RU (1) | RU2760558C9 (enExample) |
| TW (1) | TWI787260B (enExample) |
| WO (1) | WO2018204713A1 (enExample) |
| ZA (1) | ZA201908006B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7514078B2 (ja) * | 2017-05-04 | 2024-07-10 | エクシーバ ゲーエムベーハー | 新規な組成物、組み合わせ及びその方法を用いた標的薬物救済 |
| TW202102219A (zh) * | 2019-03-18 | 2021-01-16 | 美商艾賓爾製藥公司 | 使用氘化右旋美沙芬(dextromethorphan)及奎尼丁(quinidine)治療精神分裂症之負面徵候之方法 |
| WO2020246143A1 (ja) * | 2019-06-06 | 2020-12-10 | Jsr株式会社 | 感放射線性樹脂組成物、レジストパターン形成方法及び化合物 |
| AU2021276656A1 (en) | 2020-05-19 | 2022-11-24 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| CN116473077B (zh) * | 2023-05-08 | 2025-04-11 | 广东方中高新材料有限公司 | 一种n,n配位的镓配合物抗菌剂的合成和应用 |
| CN116473073A (zh) * | 2023-05-08 | 2023-07-25 | 广东方中高新材料有限公司 | 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法 |
| CN119432479B (zh) * | 2023-08-04 | 2025-10-03 | 中国石油天然气股份有限公司 | 柴油机润滑油组合物及其制备方法 |
| CN120987847A (zh) * | 2024-11-29 | 2025-11-21 | 江苏恩华药业股份有限公司 | 一种氢溴酸右美沙芬的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4241065A (en) * | 1979-07-02 | 1980-12-23 | E. I. Du Pont De Nemours And Company | Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both |
| US4950658A (en) * | 1988-12-06 | 1990-08-21 | Board Of Trustees Of Southern Illinois Univ. | Method of medical treatment of Alzheimer's disease |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| MX2008009947A (es) | 2006-02-03 | 2008-10-20 | Avanir Pharmaceuticals | Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos. |
| EP2522667B1 (en) * | 2007-05-01 | 2014-08-20 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| AU2008254585B2 (en) * | 2007-05-21 | 2013-09-26 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
| US8017623B2 (en) * | 2008-07-03 | 2011-09-13 | Trinity Laboratories, Inc. | Dextromethorphan hydrochloride |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2964022B1 (en) * | 2013-03-07 | 2019-11-06 | Mindlab LLC | Pain medicine combination and uses thereof |
| CA2907357A1 (en) * | 2013-03-15 | 2014-09-18 | Kinemed, Inc. | Biomarkers |
| SG11201701645WA (en) * | 2014-09-14 | 2017-04-27 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
| JP7096813B2 (ja) * | 2016-08-26 | 2022-07-06 | エクシーバ ゲーエムベーハー | 組成物及びその方法 |
| JP7514078B2 (ja) * | 2017-05-04 | 2024-07-10 | エクシーバ ゲーエムベーハー | 新規な組成物、組み合わせ及びその方法を用いた標的薬物救済 |
-
2018
- 2018-05-03 JP JP2019560216A patent/JP7514078B2/ja active Active
- 2018-05-03 AU AU2018261654A patent/AU2018261654A1/en not_active Abandoned
- 2018-05-03 CN CN201880037396.3A patent/CN110831584B/zh active Active
- 2018-05-03 EP EP18794381.6A patent/EP3618819A4/en active Pending
- 2018-05-03 KR KR1020197035796A patent/KR20200062078A/ko not_active Ceased
- 2018-05-03 MA MA049464A patent/MA49464A/fr unknown
- 2018-05-03 CA CA3138116A patent/CA3138116A1/en active Pending
- 2018-05-03 WO PCT/US2018/030978 patent/WO2018204713A1/en not_active Ceased
- 2018-05-03 KR KR1020217033764A patent/KR102444803B1/ko active Active
- 2018-05-03 BR BR112019022902A patent/BR112019022902A2/pt not_active Application Discontinuation
- 2018-05-03 RU RU2019137004A patent/RU2760558C9/ru active
- 2018-05-03 CA CA3062452A patent/CA3062452C/en active Active
- 2018-05-04 TW TW107115320A patent/TWI787260B/zh active
-
2019
- 2019-10-31 IL IL270326A patent/IL270326B2/en unknown
- 2019-12-02 ZA ZA2019/08006A patent/ZA201908006B/en unknown
-
2021
- 2021-08-13 AU AU2021215274A patent/AU2021215274B2/en active Active
-
2023
- 2023-07-21 JP JP2023119151A patent/JP2023143940A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023143940A5 (enExample) | ||
| JP2025013344A5 (enExample) | ||
| JP6406713B2 (ja) | 低用量薬剤によるうつ病および他の疾患の処置 | |
| JP5543200B2 (ja) | ３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）−フェノール及びｎｓａｉｄ含む医薬の組合せ | |
| JP2008538741A (ja) | 鬱病の治療用及び／又は予防用の医薬組成物 | |
| JP2004526788A5 (enExample) | ||
| CN101431990B (zh) | 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合 | |
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| JP2014062126A5 (enExample) | ||
| JP2009541443A5 (enExample) | ||
| JP2002226401A (ja) | うつ病の併用療法 | |
| RU2404771C3 (ru) | Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты | |
| JPH06157301A (ja) | トラマドール物質及び非ステロイド抗炎症薬を含んで成る組成物 | |
| WO2004071431A2 (en) | Method and composition for treating neurodegenerative disorders | |
| JP2008521827A5 (enExample) | ||
| JP2009527525A (ja) | 尿失禁治療用のベンゾイミダゾロン誘導体 | |
| JP2002515435A (ja) | 鬱病処置のための組合せ治療 | |
| CN116209657A (zh) | 用于精神障碍或增强的2-氨基茚满化合物 | |
| US20170151197A1 (en) | Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof | |
| MXPA02004410A (es) | Tratamiento de combinacion para la ansiedad y la depresion. | |
| MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
| JP2021530488A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| JPH02138214A (ja) | 不安を治療する方法 | |
| JP7208139B2 (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| RU2010147881A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА |